Kalshi expands prediction market offerings to include FDA regulatory outcomes and clinical trial results

Prediction platform Kalshi is launching contracts tied to pharmaceutical clinical trial outcomes and FDA approval decisions. The firm claims this mechanism will aggregate market sentiment and provide real-time probability tracking for drug development, though it introduces new regulatory and ethical questions regarding the influence of betting on medical research.